Position 5-7: Finalization

Muscle

Select the specific approach and device combination to identify the exact billable procedure code.

Approach 0

Open

Device D

XW020D8 Introduction Muscle to New Technology Group 8 with Engineered Allogeneic Thymus Tissue, Open Approach
Approach 3

Percutaneous

Device S

XW023S6 Introduction Muscle to New Technology Group 6 with COVID-19 Vaccine Dose 1, Percutaneous Approach

Device T

XW023T6 Introduction Muscle to New Technology Group 6 with COVID-19 Vaccine Dose 2, Percutaneous Approach

Device U

XW023U6 Introduction Muscle to New Technology Group 6 with COVID-19 Vaccine, Percutaneous Approach

Device V

XW023V7 Introduction Muscle to New Technology Group 7 with COVID-19 Vaccine Dose 3, Percutaneous Approach

Device W

XW023W7 Introduction Muscle to New Technology Group 7 with COVID-19 Vaccine Booster, Percutaneous Approach

Device X

XW023X7 Introduction Muscle to New Technology Group 7 with Tixagevimab and Cilgavimab Monoclonal Antibody, Percutaneous Approach

Device Y

XW023Y7 Introduction Muscle to New Technology Group 7 with Other New Technology Monoclonal Antibody, Percutaneous Approach